Seattle Cancer Care Alliance (SCCA) has one of the most active Merkel cell carcinoma clinical and research programs in the world. Patients with Merkel cell carcinoma are treated at the Multidisciplinary Skin Oncology Clinic at SCCA by a team of experienced doctors who are experts in surgery, medical oncology, radiation oncology, and dermatology.
Merkel cell carcinoma patients at SCCA are supported by a nursing staff with extensive experience in taking care of the physical and emotional needs of skin cancer patients. Patients also have access to a social worker, a nutritional counselor, and other supportive care services.
SCCA’s team is well known for providing innovative therapies, including vaccine protocols, gene therapy, chemotherapy, and immunotherapy. In 2017 immune checkpoint inhibitor avelumab (Bavencio) became the first FDA-approved treatment for metastatic Merkel cell carcinoma after being studied in a clinical trial, for which SCCA was one of the leading sites.
SCCA was formed, in part, to bring promising new treatments to patients faster. This means that people who have Merkel cell carcinoma will find more treatment options at SCCA than might be found elsewhere, including participation in one of the clinical studies conducted at SCCA and its alliance partners, Fred Hutch and UW Medicine.